VIDEO: ADT break may help therapy responders in metastatic prostate cancer

CHICAGO — In this video, Atish D. Choudhury, MD, PhD, discusses a study of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer who respond well to androgen receptor pathway inhibitors.Findings from the single-arm, phase 2 A-DREAM trial were presented at ASCO Annual Meeting.